This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Michel, N.
Right arrow Articles by Garin, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michel, N.
Right arrow Articles by Garin, B.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, December 2005, p. 6060-6063, Vol. 43, No. 12
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.12.6060-6063.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Distribution of Streptococcus pneumoniae Serotypes Responsible for Penicillin Resistance and the Potential Role of New Conjugate Vaccines in New Caledonia

N. Michel,1,{dagger} M. Watson,2,{ddagger} F. Baumann,1 P. Perolat,1 and B. Garin1*

Institut Pasteur de Nouvelle Calédonie, Dakar, Senegal,1 The NSW Pneumococcal Reference Laboratory, Children's Hospital at Westmead, Department of Microbiology, Westmead, New South Wales, Australia2

Received 24 March 2005/ Returned for modification 28 April 2005/ Accepted 8 September 2005

Invasive pneumococcal disease is a significant cause of morbidity and mortality worldwide. The aim of this study was to establish the serotypes responsible for pneumococcal disease and the serotypes responsible for penicillin resistance in Noumea, New Caledonia. Isolates of Streptococcus pneumoniae from all body sites referred to the Microbiology Department of the Pasteur Institute in New Caledonia between May 1999 and May 2001 had serotyping and susceptibility testing performed. Basic demographic data on patients were also collected. A total of 298 isolates were included in the study. The most common serotypes were types 1 (20%), 23F (10%), 12F (8%), 19F (8%), and 6B (5%). The serotype distribution differed significantly with age, site of collection, and ethnicity. Overall, 280 of 298 (94%) of the isolates had serogroups that are included in the 23-valent vaccine. However, only 14 of 20 (70%) of the isolates associated with invasive disease from children younger than 5 years of age and 26 of 113 (23%) of invasive isolates from patients more than 5 years of age were included in the new 7-valent conjugate vaccine. Overall, reduced susceptibility to penicillin was found in 43 of 298 (14.4%) of the isolates, with 13% falling into the intermediate resistance category and only 5 (2%) being high-level resistant. A higher prevalence of penicillin resistance occurred in younger age groups and in European patients and involved specifically certain serotypes. The 7-valent conjugate pneumococcal vaccine has potential benefit for the New Caledonian population under 5 years of age and should be considered for future vaccines schedules.

* Corresponding author. Mailing address: Institut Pasteur, BP 220, Dakar, Sénégal. Phone: (221) 839 92 30. Fax: (221) 822 70 52. E-mail: bgarin{at}pasteur.sn.

{dagger} Present address: 2368 Route du Bouchet, 74400, Chamonix, France.

{ddagger} Present address: St. John of God Department of Pathology, Hollywood Private Hospital, Monash Ave., Nedlands 6009, Western Australia.

Journal of Clinical Microbiology, December 2005, p. 6060-6063, Vol. 43, No. 12
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.12.6060-6063.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»